Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Grifols International","sponsor":"Endpoint Health","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols Signs Global Collaboration Agreement with Endpoint Health to Develop and Commercialize Antithrombin III for Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Grifols International"},{"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar reports positive results for Aplidin\u00ae against coronavirus HCoV-229E\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Peptide","graph2":"PharmaMar"},{"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Approves the Start of the Phase III NEPTUNO Trial with PharmaMar's Aplidin\u00ae (Plitidepsin) for the Treatment of Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"PharmaMar"},{"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"SOM Biotech"},{"company":"Microviable Therapeutics","sponsor":"Inmunomet Intolerancia y Disbiosis SL","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company\u00b4s Microbiota-Derived Biotherapeutic Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Microviable Therapeutics"}]

Microviable Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products

Details:

Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage, including lead product, MVT-201, at pre-clinical stage with positive results, and it is an unique biological drug for undisclosed targets.

Lead Product(s): MVT-201

Therapeutic Area: Infections and Infectious Diseases Product Name: MVT-201

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Inmunomet Intolerancia y Disbiosis SL

Deal Size: $1.6 million Upfront Cash: Undisclosed

Deal Type: Financing April 19, 2022

ASK
US

Upload
your Pipeline Activity

Grifols International

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Grifols Signs Global Collaboration Agreement with Endpoint Health to Develop and Commercialize Antithrombin III for Sepsis

Details:

As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of Antithrombin III (AT-III), a plasma protein that treats patients with blood clotting issues.

Lead Product(s): Antithrombin III

Therapeutic Area: Infections and Infectious Diseases Product Name: AT-III

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Endpoint Health

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration February 24, 2022

ASK
US

Upload
your Pipeline Activity

PharmaMar

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UK Approves the Start of the Phase III NEPTUNO Trial with PharmaMar's Aplidin® (Plitidepsin) for the Treatment of Patients with COVID-19

Details:

Pharma Mar has obtained MHRA approval for UK patients to participate in the Phase III NEPTUNO clinical trial, which will determine the efficacy of Aplidin® for the treatment of hospitalized patients with moderate COVID-19 infection.

Lead Product(s): Plitidepsin

Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 17, 2021

ASK
US

Upload
your Pipeline Activity

SOM Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2

Details:

In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.

Lead Product(s): Eravacycline

Therapeutic Area: Infections and Infectious Diseases Product Name: TP-434

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 19, 2020

ASK
US

Upload
your Pipeline Activity

PharmaMar

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

PharmaMar reports positive results for Aplidin® against coronavirus HCoV-229E

Details:

PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.

Lead Product(s): Plitidepsin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 13, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY